Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of FCN-159 in adults with symptomatic unresectable NF1-associated plexiform neurofibromas
CTR20231840Phase 3Active
- Sponsor
- Fosun Pharma
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of luvometinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN), sponsored by Fosun Pharma. Started Jul 2023; status: active.
02
Drugs
luvometinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on CTR20231840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231840.